Introduction to the Optimum Patient Guide to the Dupixent Lawsuit

  • Recent studies on Dupixent and Cancer:  Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.
  • Who Is Eligible for a Dupixent Lawsuit. If you who were prescribed Dupixent and were subsequently diagnosed with T-Cell Lymphoma or experienced other severe Dupixent side effects, call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation as you may be eligible for a Dupixent Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected]

THE DUPIXENT COMMON SIDE EFFECTS PROFILE

 

Dupixent Lawsuit

Dupixent Lawsuit Status (as of November 2025)

  • First Lawsuit:  The first known Dupixent Lawsuit for wrongful death lawsuit was filed in a federal court in Tennessee in October 2025. The lawsuit alleges the drug caused a woman’s fatal T-cell lymphoma and that the manufacturers failed to provide adequate warnings.
  • FDA Investigation: The U.S. Federal and Drug Administration (FDA) is formally investigating the potential link and evaluating whether new cancer warnings should be added to the Dupixent label. The current label does not mention a CTCL risk.
  • Settlements: No settlements have been reached in any Dupixent Lawsuit , and there are no jury verdicts, making it difficult to estimate potential settlement amounts.

SAFETY AND EFFICACY DATA OF DUPIXENT SIDE EFFECTS FROM CLINICAL TRIALS

 

Dupixent Lawsuit

Research and the Link Between Dupixent and Cancer

Several medical reports and studies including the Nation Library of Medicine have suggested that Dupixent may be tied to an increased risk of CTCL.

    • A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
    • A second study using TriNetX data (Mandel et al., 2024) was published in August 2024 and followed a method similar to the first study by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma.After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).
    • In September 2025, a study led by Sheng-Kai Ma and his team looked at the  patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53).

After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.

  • Acceleration of cutaneous T-cell lymphoma following dupilumab administration
    • Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema

These findings have pushed doctors to re-evaluate how and when to prescribe Dupixent — especially when patients show unusual skin reactions that don’t improve.

Scientific Evidence and Regulatory Action

Scientific studies and reports to the FDA have highlighted a potential link between Dupixent and T-cell lymphomas: 
  • FDA Investigation: The FDA is formally investigating the potential safety signal for CTCL linked to Dupixent use. This investigation began in March 2025.
    • Status: The FDA has not recalled Dupixent, but the investigation is formal and follows a pattern of regulatory actions that may include label revisions. 
  • Increased Risk Studies: Several peer-reviewed studies suggest an increased risk of CTCL in Dupixent users:

What This Means for Patients Who Suffered Dupixent and Cancer?

  • No FDA action yet: The FDA has not publicly addressed Dupixent and Cancer with a warning, although this could change as litigation progresses. 
  • Case law and evidence: The first few filed cases will likely set a precedent for how future claims are handled, including what evidence is considered and how causation is argued. 
  • Consult with a Dupixent Cancer Lawsuit:  If you are considering a Dupixent Cancer Lawsuit, it is recommended to consult with a legal professional to understand your specific situation. Call Dupixent Cancer Lawsuit Timothy L. Miles today for a free case evaluation as you may be eligible for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected].

Dupixent and Cancer

  • Dupixent and its Intended Use:  Dupixent  is a prescription injection manufactured by Sanofi and Regeneron and first approved by the FDA in 2017. It is commonly prescribed for patients with:
    • Moderate-to-severe eczema (atopic dermatitis)
    • Asthma
    • Cchronic sinusitis with nasal polyps
    • eosinophilic esophagitis
  •  Contact a Dupixent Lawyer: If you took Dupixent and subsequently developed CTCL or other serious Dupixent side effects or just have general questions, call Dupixent Lawyer Timothy L. Miles today, free of charge, for a free case evaluation as you may be eligible for a Dupixent Lawsuit and possibly entitled to substantial compensation.  (855) 846-6529 or [email protected].

Symptoms of CTCL

Symptoms of CTCL may include:

FDA APPROVAL TIMELINE FOR DUPIXENT FOR THE TREATMENT OF ATOPIC DERMATITIS 

FDA approval timeline used n Dupixent lawsuit

Patient Reports of Cancer Linked to Dupixent

  • Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA),  Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.
  • Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.
  • The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:
    • Cutaneous T-Cell Lymphoma
    • Adult T-Cell Lymphoma/Leukemia
    • T-Cell Lymphoma (general)
    • CTCL, Stage IV
    • CTCL, Stage III
    • Angioimmunoblastic T-Cell Lymphoma
    • CTCL, Stage I
    • Recurrent T-Cell Lymphoma
    • Lymphoma (unspecified)
    • Anaplastic Large Cell Lymphoma (T- and null-cell types)
    • Unclassifiable T-Cell Lymphoma

Volume of Reports:  The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.

FAERS DATABASE

Who is Eligible for a Dupixent Lawsuit?

Dupixent Lawsuit: You may be eligible if you:

  • Used Dupixent (dupilumab) as prescribed
  • Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
  • Experienced serious Dupixent side effects or worsening symptoms
  • Are within your state’s statute of limitations

Compensation in a Dupixent Lawsuit

If you are eligible for a Dupixent Cancer Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:

If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions.  Contact Dupixent Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Lawsuit and can explain more about the type of damages you are entitled to receive.  (855) 846–6529 or [email protected].

If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?

  • Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Lawyer to see if you qualify for a Dupixent Lawsuit. These are not typical cases any lawyer can litigate. Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Lawsuit and can explain more about what will happen next.  (855) 846–6529 or [email protected].
  • Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.
  • Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug.  Time is of the essence so give Dupixent Lawyer Timothy L. Miles a call today.

Contingency Fee Agreements: No Cost to Hire a Lawyer

  • Talk with a Lawyer Free of Charge: A lawyer​ can explain the process of a Dupixent Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Dupixent Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.

FREQUENTLY ASKED QUESTIONS ABOUT A DUPIXENT LAWSUIT

How Can a Dupixent Lawyer help me?

When you hire a skilled Dupixent Lawyer, they will work tirelessly to build a strong case on your behalf. This includes:
  • Thoroughly investigating the details of your case, including your medical history, Dupixent usage, and the onset of your symptoms
  • Gathering and analyzing relevant medical records, scientific studies, and other evidence to support your claims
  • Collaborating with medical experts to provide expert testimony and strengthen your case
  • Negotiating with the pharmaceutical company and their legal team to secure a fair settlement
  • Preparing and filing the necessary legal documents to initiate and progress your lawsuit
  • Representing you in court if litigation becomes necessary
By having a knowledgeable Dupixent Lawyer on your side, you can rest assured that your rights will be protected, and you will have the best possible chance of obtaining the compensation you deserve.

How can I join the Dupixent Lawsuit?

Contact Dupixent Lawyer Timothy L. Miles:  Today who can determine of you qualify for a Dupixent Cancer Lawsuit and can further explain the process. 855/846-6529 or via e-mail at [email protected]. (24/7/365).

What are the potential benefits of a Dupixent Cancer Lawsuit?

If you are eligible for a Dupixent Lawsuit, you may be entitled to substantial compensation for your medical treatment and for your pain and suffering.

How long will the Dupixent Lawsuit take to resolve?

The duration of lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.
What Is Cutaneous T-cell lymphoma?
Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing cancer of the T-cells (a type of white blood cell) that affects the skin. Symptoms often include itchy, scaly rashes, red patches, plaques, or tumors, and can mimic other skin conditions like eczema, which can delay diagnosis. In some cases, the cancer can spread from the skin to the lymph nodes or other organs. phagitis.
Key characteristics
  • Itchy, scaly patches or plaques
  • Redness on the skin
  • Thicker, raised lesions or tumors
  • Progression: CTCL is often slow-growing, but some types can be aggressive and spread to other parts of the body, such as the lymph nodes, blood, or organs like the liver or lungs.
Common types: The two most common types are mycosis fungoides and Sézary syndrome.
  • Diagnosis: Diagnosis can be challenging due to similar-looking symptoms and often involves a skin biopsy, physical exam, blood tests, and imaging.
  • Treatment: Treatments are chosen based on the stage of the cancer and can include creams, light therapy, radiation, or systemic treatments like chemotherapy or other medications.

What is cutaneous T-cell lymphoma (CTCL)?

Cutaneous T-cell lymphomas (CTCL) are a wide range and group of extremely rare cancers. Some forms grow slowly and stay in the skin. Less frequently, the cancer can spread from the skin to the blood or a lymph node. Dermatologists often work closely with oncologists (doctors who treat cancer) and other specialists to care for patients who have one of these cancers.

How many different types of CTCL are there?

There are several types. The most common types of cutaneous T-cell lymphoma, also known as CTCL cancer or CTCL, are:
  • Mycosis Fungoide (MF) – The most common type, characterized by patches, plaques, and tumors on the skin.
  • Sézary Syndrome (SS) – A more aggressive form of MF that affects the blood as well as the skin.
Other more rare types of CTCL include:
  • Lymphomatoid papulosis – A benign form of CTCL that causes small, itchy bumps on the skin.
  • Granulomatous slack skin – A rare, indolent form of CTCL that causes loose, pendulous folds of skin.
  • Anaplastic large cell lymphoma – An aggressive form of CTCL that can spread to other organs.
  • Extranodal NK/T-cell lymphoma: A rare type of CTCL that affects the skin and lymph nodes.
  • Extranodal NK/T-cell lymphoma, nasal type – A rare, aggressive lymphoma that can affect the skin, among other places.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) – A rare, slow-growing type that causes nodules deep in the fatty layer of the skin, most often on the legs.
  • Primary cutaneous peripheral T-cell lymphoma (unspecified) – This is a category for rare entities that do not fit into other classifications.

Contact Timothy L. Miles Today About a Dupixent Cancer Lawsuit

If you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation.  855/846-6529 or via e-mail at [email protected].(24/7/365).

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Logo law office timothy l. miles used in Dupixent Lawsuit